Tirzepatide 500mcg 25tablets Oral steroids tablets

Description

Tirzepatide Oral GLP-1/GIP Dual Agonist Weight Loss Research

Compound Background

Tirzepatide is a linear, synthetic 39-amino-acid peptide modified with a C20 fatty diacid moiety that functions as a high-affinity dual agonist for both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. [Tirzepatide agonizes GIP and GLP-1 receptors]. This molecule serves as a primary research benchmark for investigating the synergistic effects of multi-incretin signaling on metabolic homeostasis. Unlike single-agonist analogs, this dual-ligand system explores the cross-talk between nutrient-stimulated hormone secretion and energy expenditure pathways. Incretin signaling is precise.

Specification Sheet

• CAS Number: 2023788-19-2
• Molecular Formula: C225H348N48O68
• Molecular Weight: 4813.53 g/mol
• Purity: >99.0% via HPLC-UV
• Appearance: Fine white crystalline powder

Mode of Action

The biochemical activity of Tirzepatide is defined by its ability to engage GIP and GLP-1 receptors simultaneously. At the molecular level, the molecule acts as a full agonist at the GIP receptor, mimicking the activity of the native GIP hormone to modulate lipid metabolism while the ligand binds to the GLP-1 receptor with approximately 20-fold less potency than native GLP-1, promoting a biased signaling profile that favors insulinotropic activity over receptor internalization. This defines the first semantic triple: [Tirzepatide agonizes GIP receptors]. Secondly, the resulting dual-receptor occupancy stimulates glucose-dependent insulin secretion from pancreatic beta cells. This establishes the second triple: [Dual agonism stimulates insulin secretion]. Furthermore, this dual activation delays gastric emptying and suppresses postprandial glucagon release, establishing a potent glycemic control environment. This forms the third triple: [Dual agonism slows gastric transit]. Quantitatively, the compound possesses a systemic half-life of approximately 117 hours ($t_{1/2} approx 5$ days) in research models. In comparative studies, Tirzepatide is distinguished from Semaglutide by the inclusion of the GIP component; while Semaglutide focuses exclusively on GLP-1-mediated satiety, Tirzepatide explores additional GIP-mediated improvements in white adipose tissue sensitivity and lipid clearance kinetics.

Research Observations

• Profound Glycemic Stabilization: Users in research models report significant reductions in fasted blood glucose and stabilized hemoglobin A1c markers.
• Selective Adipose Mobilization: Controlled trials show marked fat loss while maintaining lean myofibrillar density during metabolic assays.
• Appetite Suppression: Based on community feedback, the dual-agonist approach creates a prolonged sense of satiety and reduced hedonic food cravings.
• Improved Lipid Profiles: Aggregated data shows a favorable shift in triglyceride and VLDL concentrations.
• Cardiovascular Resilience: Research models have observed localized improvements in systemic blood pressure and inflammatory markers.

Key Points:
Tirzepatide Oral represents a premier research tool for investigating the targeted dual-activation of incretin pathways and the molecular pathways of sustained metabolic regulation.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.